Medical device developer Imricor (IMR) announces first successful ablation procedure since lockdown eased in Europe

2021-02-24 02:11:18 (AET) by Ring Zhang   642


Imricor Medical Systems (ASX: IMR) announced the commencement of procedures at the Netherlands-based Maastricht University Medical Centre+ (MUMC+), following the COVID-19 lockdown measures eased in Europe.

Imricor Medical Systems (ASX: IMR), an ASX-Listed medical device developer specialised in MRI-guided cardiac ablation products, today announced the commencement of procedures at Netherlands-based Maastricht University Medical Centre+ (MUMC+), following the COVID-19 lockdown measures eased in Europe.

The share price of IMR moved up by 1.36% today to $2.23.
text

The team at MUMC+ has successfully performed two atrial flutter ablation procedures earlier today using the company’s full suite of products, including its prime product Vision-MR Ablation Catheter, in an Interventional Cardiac Magnetic Resonance Imaging (iCMR) lab facility.

MUMC+ Electrophysiologist, Dr. Marisevi Chaldoupi, MD PhD, commented that they realised the limitation in the past, and now can see ‘what we are doing’. He added: “While we have just started in iCMR, it is obvious to see the future of this technology and where it will take us and patient treatment.”

The medical device developer confirmed that it would continue to schedule training and installation at new sites and supporting the recommencement of procedures at existing sites as restrictions associated with COVID-19 started to lift across the globe.

A bit intro about Imricor

Imicor is a leading developer of innovative MRI-compatible medical devices which are used to carry out MRI-guided cardiac catheter ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac catheter ablation procedures.

The Vision-MR Ablation Catheter is the Company’s prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters.


Source: IMR ASX announcement MAASTRICHT UNIVERISITY MEDICAL CENTER COMMENCES PROCEDURES


标签:

声明:这些资讯属于事实信息,仅供参考,不应被视为投资建议或用于投资决策

版权所有,转载需注明出处:61 澳洲财经资讯 news.61financial.com.au

商务合作请联系 support@61financial.com.au


61 澳洲财经资讯邮件订阅服务,每日为您推荐最新澳洲财经资讯


推广

cover
诉讼对特斯拉股价的重压

在最新发生的争议中,如果特斯拉和SolarCity的审判结果不利于特斯拉CEO埃隆·马斯克(Elon Musk),特斯拉可能被迫对股东进行赔偿。这对特斯拉股价有何影响?

相关文章

cover
医疗设备开发商Imricor发出季度报告,三大市场扩展策略全力推进

磁共振引导心脏消融产品的全球领导者Imricor Medical Systems (ASX:IMR) 今日发布其截至2021年6月30日的季度现金流报告并提供财务和运营业绩的季度更新。季度内,该公司新增一个新站点——Helios Hospital Berlin-Buch。公司表示,虽然其分销管道仍然强劲,但由于冠状病毒病 (COVID-19) 带来的长期影响,以及6月和7月的接种率低于预期,新iCMR站点的合同签署进度比预期要慢。

cover
脱水简报- Imricor Medical Systems个股分析

Imricor Medical Systems,Inc. (ASX:IMR)是一家位于美国的医疗设备公司。该公司专注于设计,制造和销售与磁共振成像(MRI)兼容的产品,这些产品可用于治疗心律失常的心脏导管消融手术。

cover
心脏消融设备公司Imricor签署其第十个iCMR实验室站点

可视化心脏消融设备公司Imricor Medical Systems,Inc.( ASX:IMR)宣布,已与德国柏林布赫Helios综合性医院(Helios Hospital Berlin-Buch)签署协议,成为第十个建立iCMR(介入性心脏磁共振成像)实验室的临床站点,将采用Imricor的产品在由MRI引导的环境下进行可视化的心脏消融手术。